{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T01:53:24Z","timestamp":1788314004847,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470136"],"award-info":[{"award-number":["82470136"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82570173"],"award-info":[{"award-number":["82570173"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2025-I2M-XHZY-034"],"award-info":[{"award-number":["2025-I2M-XHZY-034"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["T-B-085"],"award-info":[{"award-number":["T-B-085"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin Municipality","doi-asserted-by":"publisher","award":["25JCLZJC00480"],"award-info":[{"award-number":["25JCLZJC00480"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010041","name":"Tianjin Municipal Science and Technology Committee","doi-asserted-by":"publisher","award":["25ZXZSSS00510"],"award-info":[{"award-number":["25ZXZSSS00510"]}],"id":[{"id":"10.13039\/501100010041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2507802"],"award-info":[{"award-number":["2023YFC2507802"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012580","name":"Natural Science Foundation of Tianjin Science and Technology Correspondent Project","doi-asserted-by":"publisher","award":["25JCLMJC00700"],"award-info":[{"award-number":["25JCLMJC00700"]}],"id":[{"id":"10.13039\/501100012580","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.eclinm.2026.103849","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:04:57Z","timestamp":1774530297000},"page":"103849","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Daratumumab in patients with immune thrombocytopenia: a single-center, open-label, phase 2 trial"],"prefix":"10.1016","volume":"94","author":[{"given":"Yunfei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengjie","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7096-1056","authenticated-orcid":false,"given":"Jia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongfeng","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mankai","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renchi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7769-7377","authenticated-orcid":false,"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eclinm.2026.103849_bib1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/bjh.14515","article-title":"State of the art \u2013 how I manage immune thrombocytopenia","volume":"177","author":"Cooper","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.eclinm.2026.103849_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103820","article-title":"Recent advances in the mechanisms and treatment of immune thrombocytopenia","volume":"76","author":"Provan","year":"2022","journal-title":"eBioMedicine"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103849_bib3","doi-asserted-by":"crossref","DOI":"10.1007\/s44466-025-00001-5","article-title":"Phospholipid metabolism in innate immunity and inflammation: from basic to clinic","volume":"1","author":"Liu","year":"2025","journal-title":"Immun Inflamm"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103849_bib4","doi-asserted-by":"crossref","DOI":"10.1007\/s44466-025-00014-0","article-title":"NF-\u03baB: master regulator of cellular responses in health and disease","volume":"1","author":"Hoffmann","year":"2025","journal-title":"Immun Inflamm"},{"issue":"9","key":"10.1016\/j.eclinm.2026.103849_bib5","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1111\/jth.14227","article-title":"Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults","volume":"16","author":"Piel-Julian","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"21","key":"10.1016\/j.eclinm.2026.103849_bib6","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood-2017-03-754119","article-title":"Clinical updates in adult immune thrombocytopenia","volume":"129","author":"Lambert","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.eclinm.2026.103849_bib7","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2015-07-659656","article-title":"High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial","volume":"127","author":"Wei","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.eclinm.2026.103849_bib8","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.eclinm.2026.103849_bib9","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ajh.25680","article-title":"Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia","volume":"95","author":"Newland","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.eclinm.2026.103849_bib10","article-title":"Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia the phase 3 LUNA3 study","volume":"145","author":"David","year":"2025","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.eclinm.2026.103849_bib11","doi-asserted-by":"crossref","DOI":"10.1172\/JCI153580","article-title":"High-affinity autoreactive plasma cells disseminate through multiple organs in patients with immune thrombocytopenic purpura","volume":"132","author":"Canales-Herrerias","year":"2022","journal-title":"J Clin Investig"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103849_bib12","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1172\/JCI65689","article-title":"B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells","volume":"123","author":"Mah\u00e9vas","year":"2013","journal-title":"J Clin Investig"},{"key":"10.1016\/j.eclinm.2026.103849_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.597959","article-title":"CD38: an immunomodulatory molecule in inflammation and autoimmunity","volume":"11","author":"Piedra-Quintero","year":"2020","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.eclinm.2026.103849_bib14","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/s41591-023-02479-1","article-title":"Daratumumab monotherapy for refractory lupus nephritis","volume":"29","author":"Roccatello","year":"2023","journal-title":"Nat Med"},{"issue":"19","key":"10.1016\/j.eclinm.2026.103849_bib15","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1182\/bloodadvances.2018020883","article-title":"Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation","volume":"2","author":"Schuetz","year":"2018","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.eclinm.2026.103849_bib16","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bjh.18854","article-title":"Daratumumab for refractory immune-mediated thrombotic thrombocytopenic purpura","volume":"202","author":"Aggarwal","year":"2023","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103849_bib17","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00277-022-05035-y","article-title":"Long-term complete remission of refractory severe idiopathic immune thrombocytopenia (ITP) treated with daratumumab","volume":"102","author":"Str\u00fc\u00dfmann","year":"2023","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.eclinm.2026.103849_bib18","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/bloodadvances.2019001215","article-title":"Successful treatment of thrombocytopenia with daratumumab after allogeneic transplant: a case report and literature review","volume":"4","author":"Migdady","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.eclinm.2026.103849_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/ITT.S487895","article-title":"Daratumumab and romiplostim combined therapy for a long-standing refractory primary immune Thrombocytopenia \u2013 case report","volume":"14","author":"Zoubi","year":"2025","journal-title":"ImmunoTargets Ther"},{"issue":"23","key":"10.1016\/j.eclinm.2026.103849_bib20","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMoa2400409","article-title":"A novel Anti-CD38 monoclonal antibody for treating immune thrombocytopenia","volume":"390","author":"Chen","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.103849_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-084314","article-title":"Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial","volume":"391","author":"Chen","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2026.103849_bib22","series-title":"International Society on Thrombosis and Haemostasis (ISTH) Congress","article-title":"Safety, tolerability, and efficacy of mezagitamab (TAK-079) in chronic or persistent primary immune thrombocytopenia: interim results from a phase 2, randomized, double-blind, placebo-controlled study","author":"Kuter","year":"2024"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103849_bib23","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2025017279","article-title":"Safety and efficacy of daratumumab in immune thrombocytopenia","volume":"10","author":"Tsykunova","year":"2026","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.eclinm.2026.103849_bib24","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.eclinm.2026.103849_bib25","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103849_bib26","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.eclinm.2026.103849_bib27","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1056\/NEJMc2501527","article-title":"Daratumumab in relapsed or refractory pediatric immune thrombocytopenia","volume":"392","author":"Sun","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103849_bib28","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-021-01047-9","article-title":"A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia","volume":"14","author":"Mei","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"23","key":"10.1016\/j.eclinm.2026.103849_bib29","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2017-04-748707","article-title":"Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: final results of the EXTEND study","volume":"130","author":"Wong","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.eclinm.2026.103849_bib30","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood.2024024250","article-title":"Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice","volume":"144","author":"Gonz\u00e1lez-L\u00f3pez","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103849_bib31","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/ajh.26473","article-title":"Single-dose versus low-dose rituximab in corticosteroid-resistant or relapsed ITP: a multicenter, randomized, controlled study","volume":"97","author":"Ni","year":"2022","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.eclinm.2026.103849_bib32","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/bjh.17334","article-title":"Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study","volume":"193","author":"Lucchini","year":"2021","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.eclinm.2026.103849_bib33","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.3324\/haematol.2021.279751","article-title":"Antiplatelet antibody predicts platelet desialylation and apoptosis in immune thrombocytopenia","volume":"107","author":"Zheng","year":"2022","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.eclinm.2026.103849_bib34","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/blood-2005-06-009761","article-title":"Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIb\u03b1 antibodies","volume":"108","author":"Webster","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.eclinm.2026.103849_bib35","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/bjh.14782","article-title":"GPIIb\/IIIa autoantibody predicts better rituximab response in ITP","volume":"182","author":"Feng","year":"2018","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103849_bib36","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/jth.12524","article-title":"Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study","volume":"12","author":"Peng","year":"2014","journal-title":"J Thromb Haemost"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026000969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026000969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:11:36Z","timestamp":1778904696000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026000969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":36,"alternative-id":["S2589537026000969"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.103849","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Daratumumab in patients with immune thrombocytopenia: a single-center, open-label, phase 2 trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.103849","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103849"}}